Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach—an Indian experience

[1]  M. Toruner,et al.  Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study. , 2020, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  M. Dubinsky,et al.  Dashboards for Therapeutic Monoclonal Antibodies: Learning and Confirming , 2018, The AAPS Journal.

[3]  D. Mould,et al.  Prediction of Individual Serum Infliximab Concentrations in Inflammatory Bowel Disease by a Bayesian Dashboard System , 2018, Journal of clinical pharmacology.

[4]  M. Silverberg,et al.  Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis , 2018, Journal of Crohn's & colitis.

[5]  O. Féres,et al.  Infliximab Trough Levels and Quality of Life in Patients with Inflammatory Bowel Disease in Maintenance Therapy , 2018, Gastroenterology research and practice.

[6]  R. Omdal,et al.  Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn’s disease , 2018, Therapeutic advances in gastroenterology.

[7]  Swarup A. V. Shah,et al.  Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity , 2018, Drug metabolism and personalized therapy.

[8]  M. Sparrow,et al.  Therapeutic drug monitoring in inflammatory bowel disease: too little too early?-comments on the American Gastroenterology Association Guideline. , 2017, Translational gastroenterology and hepatology.

[9]  A. Ford,et al.  Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease , 2017, Inflammatory bowel diseases.

[10]  H. Huynh,et al.  Therapeutic drug monitoring was helpful in guiding the decision‐making process for children receiving infliximab for inflammatory bowel disease , 2017, Acta paediatrica.

[11]  C. Ivantes,et al.  IMPORTANCE OF MEASURING LEVELS OF INFLIXIMAB IN PATIENTS TREATING INFLAMMATORY BOWEL DISEASE IN A BRAZILIAN COHORT. , 2017, Arquivos de gastroenterologia.

[12]  Siddharth Singh,et al.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. , 2017, Gastroenterology.

[13]  T. Van Stappen,et al.  Current Practice for Therapeutic Drug Monitoring of Biopharmaceuticals in Inflammatory Bowel Disease , 2017, Therapeutic drug monitoring.

[14]  C. Langner,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. , 2017, Journal of Crohn's & colitis.

[15]  O. Ahmad,et al.  Anti-TNFS More Frequently Stopped Due to Loss of Response in British Asians with Crohn's Disease: A Single Centre Retrospective Analysis , 2017 .

[16]  S. Kugathasan,et al.  Infliximab Optimization Based on Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease , 2017, Journal of pediatric gastroenterology and nutrition.

[17]  M. DeMarco,et al.  The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience , 2016, Canadian journal of gastroenterology & hepatology.

[18]  M. Hull,et al.  Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease. , 2016, Journal of Crohn's & colitis.

[19]  L. Denson,et al.  Practical Use of Infliximab Concentration Monitoring in Pediatric Crohn Disease , 2016, Journal of pediatric gastroenterology and nutrition.

[20]  D. Mould,et al.  Clinical Decision Support Tools: The Evolution of a Revolution , 2016, Clinical pharmacology and therapeutics.

[21]  A. Cheifetz,et al.  Use of anti-TNF drug levels to optimise patient management , 2016, Frontline Gastroenterology.

[22]  M. Dubinsky,et al.  Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD Patients , 2016, The AAPS Journal.

[23]  T. Matsui,et al.  Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial , 2015, Inflammatory bowel diseases.

[24]  D. Mould.  The Pharmacokinetics of Biologics: A Primer , 2015, Digestive Diseases.

[25]  G. D'Haens,et al.  The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease , 2015, Scandinavian journal of gastroenterology.

[26]  A. Vinks,et al.  Review article: applying pharmacokinetics to optimise dosing of anti‐TNF biologics in acute severe ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.

[27]  K. Van Steen,et al.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.

[28]  W. Sandborn,et al.  Biologic Concentration Testing in Inflammatory Bowel Disease , 2015, Inflammatory bowel diseases.

[29]  A. Moss.  Optimizing the use of biological therapy in patients with inflammatory bowel disease , 2015, Gastroenterology report.

[30]  J. Reimund,et al.  Efficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatment , 2013 .

[31]  M. Lukáš,et al.  Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. , 2013, Journal of Crohn's & colitis.

[32]  A. Olson,et al.  Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. , 2010, International journal of clinical pharmacology and therapeutics.

[33]  D. Ashby.  Bayesian statistics in medicine: a 25 year review , 2006, Statistics in medicine.

[34]  Lewis B. Sheiner,et al.  Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.

[35]  R. Jelliffe,et al.  Population Pharmacokinetic Models: Effect of Explicit Versus Assumed Constant Serum Concentration Assay Error Patterns upon Parameter Values of Gentamicin in Infants on and off Extracorporeal Membrane Oxygenation , 1994, Therapeutic drug monitoring.